StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 May 2026 16:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form 8-K Nexentis Technologies For: May 27 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nexentis+Technologies+++++For%3A+May+27/26557815.html si-local-file:///var/storage/secattach/20260527/26557815.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nexentis+Technologies+++++For%3A+May+27/26557815.html Wed, 27 May 2026 16:07:00 -0400 NXTS O.08047001 Form 8-K Nexentis Technologies For: May 27 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nexentis+Technologies+++++For%3A+May+27/26557815.html si-local-file:///var/storage/secattach/20260527/26557815.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Nexentis+Technologies+++++For%3A+May+27/26557815.html Wed, 27 May 2026 16:07:00 -0400 NXTS O.08047001 Nexentis unit achieves drug discovery milestone with improved molecule http://www.streetinsider.com/Corporate+News/Nexentis+unit+achieves+drug+discovery+milestone+with+improved+molecule/26511474.html <p>Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its subsidiary MitoCareX Bio Ltd. has generated an optimized hit molecule with improved pharmaceutical properties compared to the program's initial hit compound. The company described this as the first drug discovery milestone since Nexentis acquired MitoCareX.</p><p>The optimized molecule was developed using MitoCareX's MITOLINE algorithm platform, which creates 3D structural models of mitochondrial carrier proteins in the SLC25 family. The initial hit molecule underwent systematic medicinal chemistry optimization, resulting in improvements across key pharmaceutical parameters as of March 31, 2026.</p><p>MitoCareX is developing a small molecule drug candidate targeting a mitochondrial SLC25 carrier protein for http://www.streetinsider.com/Corporate+News/Nexentis+unit+achieves+drug+discovery+milestone+with+improved+molecule/26511474.html Mon, 18 May 2026 09:34:58 -0400 NXTS Nexentis subsidiary hits drug discovery milestone for cancer treatment http://www.streetinsider.com/Corporate+News/Nexentis+subsidiary+hits+drug+discovery+milestone+for+cancer+treatment/26511447.html <p>Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its subsidiary MitoCareX Bio Ltd. achieved a drug discovery milestone by generating an optimized hit molecule with improved pharmaceutical properties compared to the program's initial compound.</p><p>The milestone represents progress in MitoCareX's drug discovery program targeting mitochondrial carrier proteins in the SLC25 family for potential cancer and inflammatory metabolic disease treatments. The company used its MITOLINE algorithm platform to identify the initial hit molecule and subsequently optimized it through medicinal chemistry work completed by March 31, 2026.</p><p>MitoCareX's program focuses on developing small molecule drug candidates targeting a mitochondrial SLC25 carrier protein. The MITOLINE algorithm, http://www.streetinsider.com/Corporate+News/Nexentis+subsidiary+hits+drug+discovery+milestone+for+cancer+treatment/26511447.html Mon, 18 May 2026 09:31:04 -0400 NXTS Nexentis subsidiary hits drug discovery milestone for cancer treatment http://www.streetinsider.com/FDA/Nexentis+subsidiary+hits+drug+discovery+milestone+for+cancer+treatment/26511447.html <p>Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its subsidiary MitoCareX Bio Ltd. achieved a drug discovery milestone by generating an optimized hit molecule with improved pharmaceutical properties compared to the program's initial compound.</p><p>The milestone represents progress in MitoCareX's drug discovery program targeting mitochondrial carrier proteins in the SLC25 family for potential cancer and inflammatory metabolic disease treatments. The company used its MITOLINE algorithm platform to identify the initial hit molecule and subsequently optimized it through medicinal chemistry work completed by March 31, 2026.</p><p>MitoCareX's program focuses on developing small molecule drug candidates targeting a mitochondrial SLC25 carrier protein. The MITOLINE algorithm, http://www.streetinsider.com/FDA/Nexentis+subsidiary+hits+drug+discovery+milestone+for+cancer+treatment/26511447.html Mon, 18 May 2026 09:31:04 -0400 NXTS Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development http://www.streetinsider.com/Press+Releases/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26D+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511438.html <p align="justify">Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.</p> <p align="justify">This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that http://www.streetinsider.com/Press+Releases/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26D+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511438.html Mon, 18 May 2026 09:30:00 -0400 NXTS NXTS Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development http://www.streetinsider.com/Globe+Newswire/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26D+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511438.html <p align="justify">Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.</p> <p align="justify">This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that http://www.streetinsider.com/Globe+Newswire/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26D+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511438.html Mon, 18 May 2026 09:30:00 -0400 NXTS NXTS Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development http://www.streetinsider.com/Press+Releases/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26D+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511438.html <p align="justify">Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.</p> <p align="justify">This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that http://www.streetinsider.com/Press+Releases/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26D+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511438.html Mon, 18 May 2026 09:30:00 -0400 NXTS NXTS Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development http://www.streetinsider.com/Globe+Newswire/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26D+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511438.html <p align="justify">Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.</p> <p align="justify">This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that http://www.streetinsider.com/Globe+Newswire/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26D+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511438.html Mon, 18 May 2026 09:30:00 -0400 NXTS NXTS Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development http://www.streetinsider.com/Press+Releases/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26amp%3BD+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511440.html <p align="justify">Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.</p> <p align="justify">This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that http://www.streetinsider.com/Press+Releases/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26amp%3BD+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511440.html Mon, 18 May 2026 09:30:00 -0400 NXTS O.08047001 Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development http://www.streetinsider.com/Globe+Newswire/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26amp%3BD+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511440.html <p align="justify">Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.</p> <p align="justify">This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that http://www.streetinsider.com/Globe+Newswire/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26amp%3BD+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511440.html Mon, 18 May 2026 09:30:00 -0400 NXTS O.08047001 Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development http://www.streetinsider.com/Press+Releases/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26amp%3BD+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511440.html <p align="justify">Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.</p> <p align="justify">This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that http://www.streetinsider.com/Press+Releases/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26amp%3BD+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511440.html Mon, 18 May 2026 09:30:00 -0400 NXTS O.08047001 Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development http://www.streetinsider.com/Globe+Newswire/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26amp%3BD+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511440.html <p align="justify">Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.</p> <p align="justify">This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that http://www.streetinsider.com/Globe+Newswire/Nexentis+Announces+MitoCareX+Bio+Achieves+Key+R%26amp%3BD+Milestone%2C+Generating+a+Substantially+Improved+Hit+Molecule+on+the+Path+to+Pre-Clinical+Development/26511440.html Mon, 18 May 2026 09:30:00 -0400 NXTS O.08047001 Nexentis subsidiary achieves drug discovery milestone http://www.streetinsider.com/Corporate+News/Nexentis+subsidiary+achieves+drug+discovery+milestone/26481557.html <p>Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its subsidiary MitoCareX Bio Ltd. has generated an optimized hit molecule with improved pharmaceutical properties compared to its initial hit compound, according to a company press release.</p><p>The milestone represents the first drug discovery achievement since Nexentis acquired MitoCareX. The optimized molecule was developed using the company's MITOLINE algorithm platform, which creates 3D structural models of mitochondrial carrier proteins in the SLC25 family.</p><p>MitoCareX's program targets a mitochondrial SLC25 carrier protein for potential treatment of cancers and inflammatory metabolic diseases. The initial hit molecule was identified through MITOLINE-enabled virtual screenings and subsequently underwent medicinal chemistry http://www.streetinsider.com/Corporate+News/Nexentis+subsidiary+achieves+drug+discovery+milestone/26481557.html Wed, 13 May 2026 07:07:48 -0400 NXTS Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone http://www.streetinsider.com/Press+Releases/Nexentis+Technologies+Announces+Optimization+of+Hit+Molecule+at+MitoCareX+Bio+Representing+Key+Drug+Discovery+Milestone/26481552.html <p align="justify"><b>MITOLINE</b><b>®</b><b>-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development</b></p> <p align="justify">Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit http://www.streetinsider.com/Press+Releases/Nexentis+Technologies+Announces+Optimization+of+Hit+Molecule+at+MitoCareX+Bio+Representing+Key+Drug+Discovery+Milestone/26481552.html Wed, 13 May 2026 07:07:00 -0400 NXTS O.08047001 Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone http://www.streetinsider.com/Globe+Newswire/Nexentis+Technologies+Announces+Optimization+of+Hit+Molecule+at+MitoCareX+Bio+Representing+Key+Drug+Discovery+Milestone/26481552.html <p align="justify"><b>MITOLINE</b><b>®</b><b>-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development</b></p> <p align="justify">Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit http://www.streetinsider.com/Globe+Newswire/Nexentis+Technologies+Announces+Optimization+of+Hit+Molecule+at+MitoCareX+Bio+Representing+Key+Drug+Discovery+Milestone/26481552.html Wed, 13 May 2026 07:07:00 -0400 NXTS O.08047001 Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone http://www.streetinsider.com/Press+Releases/Nexentis+Technologies+Announces+Optimization+of+Hit+Molecule+at+MitoCareX+Bio+Representing+Key+Drug+Discovery+Milestone/26481552.html <p align="justify"><b>MITOLINE</b><b>®</b><b>-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development</b></p> <p align="justify">Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit http://www.streetinsider.com/Press+Releases/Nexentis+Technologies+Announces+Optimization+of+Hit+Molecule+at+MitoCareX+Bio+Representing+Key+Drug+Discovery+Milestone/26481552.html Wed, 13 May 2026 07:07:00 -0400 NXTS O.08047001 Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone http://www.streetinsider.com/Globe+Newswire/Nexentis+Technologies+Announces+Optimization+of+Hit+Molecule+at+MitoCareX+Bio+Representing+Key+Drug+Discovery+Milestone/26481552.html <p align="justify"><b>MITOLINE</b><b>®</b><b>-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development</b></p> <p align="justify">Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its <b>first drug discovery milestone since its acquisition by </b>Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit http://www.streetinsider.com/Globe+Newswire/Nexentis+Technologies+Announces+Optimization+of+Hit+Molecule+at+MitoCareX+Bio+Representing+Key+Drug+Discovery+Milestone/26481552.html Wed, 13 May 2026 07:07:00 -0400 NXTS O.08047001 Nexentis receives U.S. trademark registration for MITOLINE algorithm http://www.streetinsider.com/Corporate+News/Nexentis+receives+U.S.+trademark+registration+for+MITOLINE+algorithm/26429944.html <p>Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its subsidiary MitoCareX Bio Ltd. received U.S. trademark registration from the USPTO for its MITOLINE algorithm platform.</p><p>MITOLINE is a sequence analysis and alignment algorithm designed to prepare mitochondrial carrier proteins of the SLC25 family for 3D homology modeling. The platform addresses the lack of solved 3D structures for most human mitochondrial carriers by systematically aligning and annotating amino acid sequences to enable generation of 3D comparative models.</p><p>"Securing U.S. trademark registration for MITOLINE is an important step in strengthening the distinct identity of our discovery engine as we scale MitoCareX within Nexentis," said David http://www.streetinsider.com/Corporate+News/Nexentis+receives+U.S.+trademark+registration+for+MITOLINE+algorithm/26429944.html Tue, 05 May 2026 07:32:54 -0400 NXTS Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™ http://www.streetinsider.com/Press+Releases/Nexentis+Technologies+Announces+U.S.+Trademark+Registration+Approval+for+MitoCareX%E2%80%99s+Algorithm+Platform+MITOLINE%E2%84%A2/26429939.html <p align="justify">Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” or the “Company”), a drug discovery company that is also invests in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=61lVgUYonyblKvOPw-6-Sy904TnPM74XUiywAuqNN0wW6WqBAB-M3kMMtcWYMM529LpjAtHo0u3lLHcapkK_sYXQL_gLIgiMve-pJkqvPuQ0almw5oAq0aGDNhnOvXtpIBBz9Yn2Ooa64PSb_72Wuw==" rel="nofollow" target="_blank">RTB</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1LaahuEh7FEI7Shq-Yw4WhlNcMyDCekrqwoz-JyRFkZHnRtiyQQPkxABSJWd7sTxFLGoJYvsXjaW3K0-sM6UheFWjNLx1AplPkf1QcNH6kSGODzPcD0mPrccEXZzUaGBIp9yHUVkkH3PsbavS97HDA==" rel="nofollow" target="_blank">(Ready</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=XoAqHaxWITnSY96NUV6RzKjL6p5tm7gVpiuONFpoGDy3vkWHk68l1kcEjGC6tBc5UQP8IkAPkA6albuXp8MT2P8XW2RgBv06M2b8aDh9YCUH-5kdgP_Eu7JhJ4sLnc-7O-auFpGH1QPFiqiDhU-CCA==" rel="nofollow" target="_blank">to</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=8XvffX9VwskVGOaGzfxiXCqrjseuATDXqYCw8F6K2RpKHgClTXIBlBKAG3hvRy6afY73mB7ApleLEVzt0oSihOL0XH0KEXxnOH6iNLBXuFANDRoe9xW1ldpw-iIjhl_f6PpYGoGFiQdKw-968Cxtuw==" rel="nofollow" target="_blank">Build)</a> business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has received official trademark registration from the United States Patent and Trademark Office (USPTO) for its proprietary algorithm platform, MITOLINE™.</p> <p align="justify">MITOLINE™ is MitoCareX’s proprietary sequence analysis and alignment algorithm http://www.streetinsider.com/Press+Releases/Nexentis+Technologies+Announces+U.S.+Trademark+Registration+Approval+for+MitoCareX%E2%80%99s+Algorithm+Platform+MITOLINE%E2%84%A2/26429939.html Tue, 05 May 2026 07:32:00 -0400 NXTS O.08047001 Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™ http://www.streetinsider.com/Globe+Newswire/Nexentis+Technologies+Announces+U.S.+Trademark+Registration+Approval+for+MitoCareX%E2%80%99s+Algorithm+Platform+MITOLINE%E2%84%A2/26429939.html <p align="justify">Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” or the “Company”), a drug discovery company that is also invests in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=61lVgUYonyblKvOPw-6-Sy904TnPM74XUiywAuqNN0wW6WqBAB-M3kMMtcWYMM529LpjAtHo0u3lLHcapkK_sYXQL_gLIgiMve-pJkqvPuQ0almw5oAq0aGDNhnOvXtpIBBz9Yn2Ooa64PSb_72Wuw==" rel="nofollow" target="_blank">RTB</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1LaahuEh7FEI7Shq-Yw4WhlNcMyDCekrqwoz-JyRFkZHnRtiyQQPkxABSJWd7sTxFLGoJYvsXjaW3K0-sM6UheFWjNLx1AplPkf1QcNH6kSGODzPcD0mPrccEXZzUaGBIp9yHUVkkH3PsbavS97HDA==" rel="nofollow" target="_blank">(Ready</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=XoAqHaxWITnSY96NUV6RzKjL6p5tm7gVpiuONFpoGDy3vkWHk68l1kcEjGC6tBc5UQP8IkAPkA6albuXp8MT2P8XW2RgBv06M2b8aDh9YCUH-5kdgP_Eu7JhJ4sLnc-7O-auFpGH1QPFiqiDhU-CCA==" rel="nofollow" target="_blank">to</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=8XvffX9VwskVGOaGzfxiXCqrjseuATDXqYCw8F6K2RpKHgClTXIBlBKAG3hvRy6afY73mB7ApleLEVzt0oSihOL0XH0KEXxnOH6iNLBXuFANDRoe9xW1ldpw-iIjhl_f6PpYGoGFiQdKw-968Cxtuw==" rel="nofollow" target="_blank">Build)</a> business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has received official trademark registration from the United States Patent and Trademark Office (USPTO) for its proprietary algorithm platform, MITOLINE™.</p> <p align="justify">MITOLINE™ is MitoCareX’s proprietary sequence analysis and alignment algorithm http://www.streetinsider.com/Globe+Newswire/Nexentis+Technologies+Announces+U.S.+Trademark+Registration+Approval+for+MitoCareX%E2%80%99s+Algorithm+Platform+MITOLINE%E2%84%A2/26429939.html Tue, 05 May 2026 07:32:00 -0400 NXTS O.08047001 Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™ http://www.streetinsider.com/Press+Releases/Nexentis+Technologies+Announces+U.S.+Trademark+Registration+Approval+for+MitoCareX%E2%80%99s+Algorithm+Platform+MITOLINE%E2%84%A2/26429939.html <p align="justify">Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” or the “Company”), a drug discovery company that is also invests in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=61lVgUYonyblKvOPw-6-Sy904TnPM74XUiywAuqNN0wW6WqBAB-M3kMMtcWYMM529LpjAtHo0u3lLHcapkK_sYXQL_gLIgiMve-pJkqvPuQ0almw5oAq0aGDNhnOvXtpIBBz9Yn2Ooa64PSb_72Wuw==" rel="nofollow" target="_blank">RTB</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1LaahuEh7FEI7Shq-Yw4WhlNcMyDCekrqwoz-JyRFkZHnRtiyQQPkxABSJWd7sTxFLGoJYvsXjaW3K0-sM6UheFWjNLx1AplPkf1QcNH6kSGODzPcD0mPrccEXZzUaGBIp9yHUVkkH3PsbavS97HDA==" rel="nofollow" target="_blank">(Ready</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=XoAqHaxWITnSY96NUV6RzKjL6p5tm7gVpiuONFpoGDy3vkWHk68l1kcEjGC6tBc5UQP8IkAPkA6albuXp8MT2P8XW2RgBv06M2b8aDh9YCUH-5kdgP_Eu7JhJ4sLnc-7O-auFpGH1QPFiqiDhU-CCA==" rel="nofollow" target="_blank">to</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=8XvffX9VwskVGOaGzfxiXCqrjseuATDXqYCw8F6K2RpKHgClTXIBlBKAG3hvRy6afY73mB7ApleLEVzt0oSihOL0XH0KEXxnOH6iNLBXuFANDRoe9xW1ldpw-iIjhl_f6PpYGoGFiQdKw-968Cxtuw==" rel="nofollow" target="_blank">Build)</a> business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has received official trademark registration from the United States Patent and Trademark Office (USPTO) for its proprietary algorithm platform, MITOLINE™.</p> <p align="justify">MITOLINE™ is MitoCareX’s proprietary sequence analysis and alignment algorithm http://www.streetinsider.com/Press+Releases/Nexentis+Technologies+Announces+U.S.+Trademark+Registration+Approval+for+MitoCareX%E2%80%99s+Algorithm+Platform+MITOLINE%E2%84%A2/26429939.html Tue, 05 May 2026 07:32:00 -0400 NXTS O.08047001 Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™ http://www.streetinsider.com/Globe+Newswire/Nexentis+Technologies+Announces+U.S.+Trademark+Registration+Approval+for+MitoCareX%E2%80%99s+Algorithm+Platform+MITOLINE%E2%84%A2/26429939.html <p align="justify">Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” or the “Company”), a drug discovery company that is also invests in solar energy assets based on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=61lVgUYonyblKvOPw-6-Sy904TnPM74XUiywAuqNN0wW6WqBAB-M3kMMtcWYMM529LpjAtHo0u3lLHcapkK_sYXQL_gLIgiMve-pJkqvPuQ0almw5oAq0aGDNhnOvXtpIBBz9Yn2Ooa64PSb_72Wuw==" rel="nofollow" target="_blank">RTB</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1LaahuEh7FEI7Shq-Yw4WhlNcMyDCekrqwoz-JyRFkZHnRtiyQQPkxABSJWd7sTxFLGoJYvsXjaW3K0-sM6UheFWjNLx1AplPkf1QcNH6kSGODzPcD0mPrccEXZzUaGBIp9yHUVkkH3PsbavS97HDA==" rel="nofollow" target="_blank">(Ready</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=XoAqHaxWITnSY96NUV6RzKjL6p5tm7gVpiuONFpoGDy3vkWHk68l1kcEjGC6tBc5UQP8IkAPkA6albuXp8MT2P8XW2RgBv06M2b8aDh9YCUH-5kdgP_Eu7JhJ4sLnc-7O-auFpGH1QPFiqiDhU-CCA==" rel="nofollow" target="_blank">to</a> <a target="_blank" href="https://www.globenewswire.com/Tracker?data=8XvffX9VwskVGOaGzfxiXCqrjseuATDXqYCw8F6K2RpKHgClTXIBlBKAG3hvRy6afY73mB7ApleLEVzt0oSihOL0XH0KEXxnOH6iNLBXuFANDRoe9xW1ldpw-iIjhl_f6PpYGoGFiQdKw-968Cxtuw==" rel="nofollow" target="_blank">Build)</a> business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has received official trademark registration from the United States Patent and Trademark Office (USPTO) for its proprietary algorithm platform, MITOLINE™.</p> <p align="justify">MITOLINE™ is MitoCareX’s proprietary sequence analysis and alignment algorithm http://www.streetinsider.com/Globe+Newswire/Nexentis+Technologies+Announces+U.S.+Trademark+Registration+Approval+for+MitoCareX%E2%80%99s+Algorithm+Platform+MITOLINE%E2%84%A2/26429939.html Tue, 05 May 2026 07:32:00 -0400 NXTS O.08047001 Nexentis Technologies (NXTS) files $100M mixed shelf http://www.streetinsider.com/Equity+Offerings/Nexentis+Technologies+%28NXTS%29+files+%24100M+mixed+shelf/26325264.html <p>Nexentis Technologies (NASDAQ: NXTS) files $100,000,000 mixed shelf of:</p><p>Common Stock</p><p>Preferred Stock</p><p>Subscription Rights</p><p>Debt Securities</p><p>Warrants</p><p>Units</p><p> </p> http://www.streetinsider.com/Equity+Offerings/Nexentis+Technologies+%28NXTS%29+files+%24100M+mixed+shelf/26325264.html Thu, 16 Apr 2026 16:18:01 -0400 NXTS Nexentis Technologies (NXTS) files $100M mixed shelf http://www.streetinsider.com/Corporate+News/Nexentis+Technologies+%28NXTS%29+files+%24100M+mixed+shelf/26325264.html <p>Nexentis Technologies (NASDAQ: NXTS) files $100,000,000 mixed shelf of:</p><p>Common Stock</p><p>Preferred Stock</p><p>Subscription Rights</p><p>Debt Securities</p><p>Warrants</p><p>Units</p><p> </p> http://www.streetinsider.com/Corporate+News/Nexentis+Technologies+%28NXTS%29+files+%24100M+mixed+shelf/26325264.html Thu, 16 Apr 2026 16:18:01 -0400 NXTS